Long-term outcome of patients with vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis

Long-term outcome of patients with vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis

Abstract We present the long-term outcomes of 44 patients who developed cerebral venous sinus thrombosis after vaccination with the adenoviral vector ChAdOx1 nCoV-19 COVID-19 vaccine. Assessment of the Extended Glasgow Outcome Scale was performed within 3–6 months after the initial hospital admissio...

Full description

Bibliographic Details
Main Authors: Sarah Kehr, Philipp Berg, Susanne Müller, Sarah A. Fiedler, Britta Meyer, Gabriele Ruppert-Seipp, Cornelia Witzenhausen, Marc E. Wolf, Hans H. Henkes, Doris Oberle, Brigitte Keller-Stanislawski, Markus B. Funk
Format: Article
Language:English
Published: Nature Portfolio 2022-07-01
Series:npj Vaccines
Online Access:https://doi.org/10.1038/s41541-022-00491-z
Description
Summary:Abstract We present the long-term outcomes of 44 patients who developed cerebral venous sinus thrombosis after vaccination with the adenoviral vector ChAdOx1 nCoV-19 COVID-19 vaccine. Assessment of the Extended Glasgow Outcome Scale was performed within 3–6 months after the initial hospital admissions. Patient outcomes ranged from good recovery (13 patients, 29.6%) to moderate disability (11 patients, 25.0%) and severe disability or vegetative state (6 patients, 13.6%). Fatal outcomes were reported in 14 patients (31.8%).
ISSN:2059-0105

Similar Items